http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Tomohiro Nishimura ),( Sakae Mukoyama ),( Ken-ichi Honda ),( Kiyoyuki Shigeno ),( Akihiro Yokota ) 대한지질공학회 2019 대한지질공학회 학술발표회논문집 Vol.2019 No.2
The Hokkaido Eastern Iburi Earthquake (Mw=6.6), which occurred in the early morning on September 6, 2018, resulted in extremely large number of landslides in Atsuma Town, Abira Town, Mukawa Town in Hokkaido. In addition, ground displacement occurred in a wide area including Kiyota Ward, Sapporo City, and many buildings were damaged. InSAR can extract small displacements of the ground surface over a wide area, regardless of the weather, and can quickly detect where the ground or a building may be damaged. We analyzed SAR before and 2 hours after the earthquake acquired by Sentinel-1 satellite within 24 hours after the earthquake, and identified areas where displacement is estimated to be large. As a result, significant displacements were estimated in Kiyota, Satozuka and Utsukushigaoka in Kiyota ward, Hiragishi in Toyohira ward, and Fushiko in Higashi ward, and it was predicted that the earthquake caused great damage. After SAR analisys, the aerial photograph interpretation and the detailed examination of the field survey were carried out for these areas. The damage situation by the ground displacement were found, checked the paleogeography, and the validity of the SAR analysis results was verified. The displacements area are concentrated on the artificial land where the old river channel and old valley are filled up, and the correlation between the damage and the old topography is considered to be very strong.
Drug compound characterization by mass spectrometry imaging in cancer tissue
권호정,Johan Malm,김용효,Yutaka Sugihara,Bo Baldetorp,Charlotte Welinder,Ken-ichi Watanabe,Toshihide Nishimura,Gyo¨rgy Marko-Varga,Szilvia To¨ro¨k,Bala´zs Do¨me,´ kos Ve´gva´ri,Lena Gustavsson,Thomas E. Feh 대한약학회 2015 Archives of Pharmacal Research Vol.38 No.9
MALDI mass spectrometry imaging (MSI)provides a technology platform that allows the accuratevisualization of unlabeled small molecules within the twodimensionalspaces of tissue samples. MSI has proven to bea powerful tool-box concept in the development of newdrugs. MSI allows unlabeled drug compounds and drugmetabolites to be detected and identified and quantifiedaccording to their mass-to-charge ratios (m/z) at high resolutionin complex tissue environments. Such drug characterizationin situ, by both spatial and temporal behaviorswithin tissue compartments, provide new understandings ofthe dynamic processes impacting drug uptake and metabolismat the local sites targeted by therapy. Further, MSIin combination with histology and immunohistochemistry,provides the added value of defining the context of cellbiology present at the sites of drug localization thus providinginvaluable information relating to treatment efficacy. In this report we provide mass spectrometry imagingdata within various cancers such as malignant melanoma inpatients administered with vemurafenib, a protein kinaseinhibitor that is targeting BRAF mutated proteins and thathas shown significant efficacy in restraining disease progression. We also provide an overview of other examplesof the new generation of targeted drugs, and demonstratethe data on personalized medicine drugs localization withintumor compartments within in vivo models. In these cancermodels we provide detailed data on drug and target proteinco-localization of YCG185 and sunitinib. These drugs aretargeting VEGFR2 within the angiogenesis mechanism. Our ability to resolve drug uptake at targeted sites ofdirected therapy provides important opportunities forincreasing our understanding about the mode of action ofdrug activity within the environment of disease.
Mahmood A. Hamed,Seiichi Nakata,Kazuya Shiogama,Kenji Suzuki,Ramadan H. Sayed,Yoichi Nishimura,Noboru Iwata,Kouhei Sakurai,Badawy S. Badawy,Ken-ichi Inada,Hayato Tsuge,Yutaka Tsutsumi 대한이비인후과학회 2017 Clinical and Experimental Otorhinolaryngology Vol.10 No.3
Objectives. Cholesteatoma is a nonneoplastic destructive lesion of the temporal bone with debated pathogenesis and bone resorptive mechanism. Both molecular and cellular events chiefly master its activity. Continued research is necessary to clarify factors related to its aggressiveness. We aimed to investigate the expression of Ki-67, cytokeratin 13 (CK13) and cytokeratin 17 (CK17) in acquired nonrecurrent human cholesteatoma and correlate them with its bone destructive capacity. Methods. A prospective quantitative immunohistochemical study was carried out using fresh acquired cholesteatoma tissues (n=19), collected during cholesteatoma surgery. Deep meatal skin tissues from the same patients were used as control (n=8). Cholesteatoma patients were divided into 2 groups and compared (invasive and noninvasive) according to a grading score for bone resorption based upon clinical, radiologic and intraoperative findings. To our knowledge, the role of CK17 in cholesteatoma aggressiveness was first investigated in this paper. Results. Both Ki-67 and CK17 were significantly overexpressed in cholesteatoma than control tissues (P<0.001 for both Ki-67 and CK17). In addition, Ki-67 and CK17 were significantly higher in the invasive group than noninvasive group of cholesteatoma (P=0.029, P=0.033, respectively). Furthermore, Ki-67 and CK17 showed a moderate positive correlation with bone erosion scores (r=0.547, P=0.015 and r=0.588, P=0.008, respectively). In terms of CK13, no significant difference was found between cholesteatoma and skin (P=0.766). Conclusion. Both Ki-67 and CK17 were overexpressed in cholesteatoma tissue and positively correlated with bone resorption activity. The concept that Ki-67 can be a predictor for aggressiveness of cholesteatoma was supported. In addition, this is the first study demonstrating CK17 as a favoring marker in the aggressiveness of acquired cholesteatoma.